Latest News and Press Releases

AGOURA HILLS, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTCQB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that the US...

AGOURA HILLS, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that its...

AGOURA HILLS, Calif., July 27, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN) announced the closing of the 1st tranche of financing related to the Mateon operations and spinoff of its...

AGOURA HILLS, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today the launch of its global observational study...

AGOURA HILLS, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today that it will fund observational studies for...

AGOURA HILLS, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of innovative...

AGOURA HILLS, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, has selected IQVIA to manage C001, a Phase 2 randomized,...

AGOURA HILLS, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”)  (OTCQB:MATN) announces that both Golden Mountain Partners (GMP) and Mateon have...

The licensing agreement of OT-101 to Autotelic BIO with the field of use limited to OT-101 (Trabedersen) with Interleukin-2 (OT-101/IL-2) combination became effective this week with the completion of...

TracePoint vision grid will identify workers who came in contact with a sick coworker and alert operational staff.Mateon’s patented AI camera grid system is similar to Amazon’s technology but at a...